Robert Getzenberg

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy
    Takumi Shiraishi
    James Buchanan Brady Urological Institute, Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Transl Med 9:153. 2011
  2. pmc Changing the energy habitat of the cancer cell in order to impact therapeutic resistance
    Robert H Getzenberg
    Department of Urology, and The Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States
    Mol Pharm 8:2089-93. 2011
  3. ncbi request reprint What is the future of prostate-specific antigen for the early detection of prostate cancer?
    Robert Getzenberg
    Department of Urology, Johns Hopkins Medicine, Baltimore, MD 21287, USA
    BJU Int 102:157-8. 2008
  4. doi request reprint Biomarkers for prostate cancer
    Danil V Makarov
    The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Annu Rev Med 60:139-51. 2009
  5. ncbi request reprint Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer
    Matthew E Nielsen
    Department of Urology, Johns Hopkins University School of Medicine, Marburg 143, 600 N Wolfe St, Baltimore, MD 21287 2101, USA
    World J Urol 24:499-508. 2006
  6. ncbi request reprint Urinary markers in the detection of bladder cancer: what's new?
    Matthew E Nielsen
    Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 2101, USA
    Curr Opin Urol 16:350-5. 2006
  7. ncbi request reprint Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer
    Benjamin Davies
    Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    J Urol 174:1767-70. 2005
  8. doi request reprint Biomarkers for prostate cancer
    Eddy S Leman
    The Brady Urological Institute and the Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Cell Biochem 108:3-9. 2009
  9. pmc Biomarkers for benign prostatic hyperplasia progression
    Grant W Cannon
    The Brady Urological Institute, Johns Hopkins Hospital, Marburg 121, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Curr Urol Rep 9:279-83. 2008
  10. ncbi request reprint Early identification of individuals with prostate cancer in negative biopsies
    Rajiv Dhir
    Department of Urology, University of Pittsburgh and Prostate and Urologic Cancer Program of the University of Pittsburgh Cancer Institute, Pennsylvania 15232, USA
    J Urol 171:1419-23. 2004

Research Grants

  1. MTOPS Biomarker Unit at the University of Pittsburgh
    Robert Getzenberg; Fiscal Year: 2004
  2. Specific Biomarkers in Bladder Cancer Prevention
    Robert Getzenberg; Fiscal Year: 2005
  3. VITAMIN D EFFECTS ON HUMAHN PROSTATE GROWTH
    Robert Getzenberg; Fiscal Year: 2001
  4. Conference--Prouts Neck Prostate Cancer
    Robert Getzenberg; Fiscal Year: 2006

Collaborators

Detail Information

Publications47

  1. pmc Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy
    Takumi Shiraishi
    James Buchanan Brady Urological Institute, Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Transl Med 9:153. 2011
    ..The aim of this study was to identify promising CTAs that are associated with prostate cancer (PCa) recurrence following radical prostatectomy (RP)...
  2. pmc Changing the energy habitat of the cancer cell in order to impact therapeutic resistance
    Robert H Getzenberg
    Department of Urology, and The Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States
    Mol Pharm 8:2089-93. 2011
    ..We have proposed that heat may be a major factor in determining the lasting therapeutic effect on many types of far advanced metastatic tumors...
  3. ncbi request reprint What is the future of prostate-specific antigen for the early detection of prostate cancer?
    Robert Getzenberg
    Department of Urology, Johns Hopkins Medicine, Baltimore, MD 21287, USA
    BJU Int 102:157-8. 2008
  4. doi request reprint Biomarkers for prostate cancer
    Danil V Makarov
    The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Annu Rev Med 60:139-51. 2009
    ..Future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer...
  5. ncbi request reprint Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer
    Matthew E Nielsen
    Department of Urology, Johns Hopkins University School of Medicine, Marburg 143, 600 N Wolfe St, Baltimore, MD 21287 2101, USA
    World J Urol 24:499-508. 2006
    ..An appreciation of basic epidemiological considerations informs our consideration of the state of the art and identifies specific strategies amenable to further innovation...
  6. ncbi request reprint Urinary markers in the detection of bladder cancer: what's new?
    Matthew E Nielsen
    Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 2101, USA
    Curr Opin Urol 16:350-5. 2006
    ..In the context of relative limitations of the current standard of cystoscopy and cytology, there has been burgeoning activity in the development of novel molecular urine-based markers for bladder cancer detection...
  7. ncbi request reprint Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer
    Benjamin Davies
    Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    J Urol 174:1767-70. 2005
    ..We determined if urinary survivin is influenced by the prostate and analyzed survivin levels in a healthy control population...
  8. doi request reprint Biomarkers for prostate cancer
    Eddy S Leman
    The Brady Urological Institute and the Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Cell Biochem 108:3-9. 2009
    ..This article highlights the discovery of PSA as a first blood-based biomarker for prostate cancer detection, as well as other molecular biomarkers and their potential application in detection of the disease...
  9. pmc Biomarkers for benign prostatic hyperplasia progression
    Grant W Cannon
    The Brady Urological Institute, Johns Hopkins Hospital, Marburg 121, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Curr Urol Rep 9:279-83. 2008
    ..The future does look promising as research to find novel biologic biomarkers is progressing while existing markers are optimized and validated for clinical use...
  10. ncbi request reprint Early identification of individuals with prostate cancer in negative biopsies
    Rajiv Dhir
    Department of Urology, University of Pittsburgh and Prostate and Urologic Cancer Program of the University of Pittsburgh Cancer Institute, Pennsylvania 15232, USA
    J Urol 171:1419-23. 2004
    ..The novel prostate cancer marker, EPCA, is expressed throughout the prostate of individuals with prostate cancer but not in those without the disease...
  11. doi request reprint Expression of cancer/testis antigens in prostate cancer is associated with disease progression
    Takahito Suyama
    Department of Urology, James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Prostate 70:1778-87. 2010
    ..The cancer/testis antigens (CTAs) are a unique group of proteins normally expressed in germ cells but aberrantly expressed in several types of cancers including prostate cancer (PCa). However, their role in PCa has not been fully explored...
  12. pmc Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2
    Eddy S Leman
    The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Prostate 69:1188-94. 2009
    ..19. The goals of this study are to characterize the sensitivity and specificity of the EPCA-2.19 assay, in a non-screening population, and to demonstrate that such test based has similar characteristics as the initial assay produced...
  13. ncbi request reprint Nuclear matrix proteins as biomarkers in prostate cancer
    Eddy S Leman
    Department of Urology, Cellular and Molecular Pathology Graduate Program and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pennsylvania 15232, USA
    J Cell Biochem 86:213-23. 2002
    ..This article reviews the role of NM proteins as tumor biomarkers in prostate cancer and the potential application of these proteins as therapeutic targets in the treatment of this disease...
  14. ncbi request reprint Nuclear structure as a source of cancer specific biomarkers
    Eddy S Leman
    The Johns Hopkins University School of Medicine, Department of Urology, 600 N Wolfe Street, Marburg 121, Baltimore, Maryland 21287, USA
    J Cell Biochem 104:1988-93. 2008
    ..These cancer biomarkers now serve as the basis of assays which can specifically identify individuals with cancer by sampling their blood and/or urine. In addition, these may serve as potential therapeutic targeting or imaging approaches...
  15. ncbi request reprint EPCA-2: a highly specific serum marker for prostate cancer
    Eddy S Leman
    Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Urology 69:714-20. 2007
    ..To describe the initial assessment of early prostate cancer antigen (EPCA)-2 as a serum marker for the detection of prostate cancer and to examine its sensitivity and specificity...
  16. ncbi request reprint A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia
    Grant W Cannon
    James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Urol 177:610-4; discussion 614. 2007
    ..The goal of these studies was to determine if a serum based assay to detect JM-27 could distinguish men with different forms of benign prostatic hyperplasia...
  17. ncbi request reprint Commentary on: Mobley AJ, Lam YW, Lau KM, Pais VM, Lesperance JO, Steadman B, et al. Monitoring the serological Proteome Colon, the latest modality in prostate cancer detection. J Urol 2004; 172: 331-7
    Robert H Getzenberg
    Department of Urology, University of Pittsburgh, Pennsylvania 15232, USA
    Asian J Androl 6:283. 2004
  18. ncbi request reprint Detection of prostate cancer with a blood-based assay for early prostate cancer antigen
    Barbara Paul
    Department of Urology, University of Pittsburgh and the University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Cancer Res 65:4097-100. 2005
    ..EPCA, when coupled with prostate-specific antigen, may help reduce the number of both unnecessary biopsies and undetected prostate tumors...
  19. ncbi request reprint Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers
    Eddy S Leman
    The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 67:5600-5. 2007
    ..ROC curves for CCSA-3 and CCSA-4 reveal an area under the curve of 0.94 (95% CI, 0.90-0.98%). In these initial analyses, CCSA-3 and CCSA-4 show promise as potential serum markers for detection of colorectal cancer and advanced adenomas...
  20. ncbi request reprint Functional characterization of the bladder cancer marker, BLCA-4
    Thu Suong Van Le
    Department of Urology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 10:1384-91. 2004
    ..Finally, to determine the timing of expression in relation to the observance of bladder cancer, an animal model of the disease was examined...
  21. pmc Extracellular matrix associated protein CYR61 is linked to prostate cancer development
    Katherine B D'Antonio
    The Brady Urological Institute, Baltimore, Maryland 21287, USA
    J Urol 183:1604-10. 2010
    ..Depending on cancer type these changes are linked with enhanced or inhibited tumor growth. We characterized Cyr61 in prostate cancer. Cyr61 is an integrin binding matricellular protein with altered expression in many cancer types...
  22. doi request reprint Identification of nuclear structural protein alterations associated with seminomas
    Eddy S Leman
    The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Cell Biochem 108:1274-9. 2009
    ..This is the first study to examine the role of nuclear structural proteins as potential biomarkers in testicular cancer. We are currently examining the roles of some of the identified proteins as potential biomarkers for the disease...
  23. doi request reprint Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer
    Eddy S Leman
    The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Cancer Res 14:1349-54. 2008
    ..CCSA-2 is a distinct novel colon cancer marker identified using focused proteomics...
  24. doi request reprint The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer
    Takahiro Inoue
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Prostate 68:1048-56. 2008
    ..Our aim is to find novel targets for the treatment of hormone-refractory prostate cancer (HRPC) by focusing on the composition of the nuclear matrix proteins (NMPs)...
  25. ncbi request reprint Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells
    Meral Guzey
    Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    J Cell Biochem 93:271-85. 2004
    ..These newly reported gene expression patterns provide novel information not only potential markers, but also on the genes involved in VD3 induced apoptosis in PCa...
  26. ncbi request reprint Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer
    Eddy S Leman
    Department of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pennsylvania 15232, USA
    J Cell Biochem 86:203-12. 2002
    ..Identification of these NMPs permits the development of novel markers that can characterize various stages of prostate cancer development as well as potentially therapeutic targets...
  27. doi request reprint Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells
    Takahiro Inoue
    James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, 600 North Wolfe St, Baltimore, MD 21287, USA
    Prostate 69:861-73. 2009
    ..The aim of the studies described here was to uncover some of the mechanisms by which over-expression of PURalpha attenuates cell proliferation...
  28. doi request reprint Urine-based markers in bladder cancer: future prospects
    Brian K McNeil
    James Buchanan Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD 21287, USA
    BJU Int 101:668-9. 2008
  29. doi request reprint Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity
    Yu Zeng
    Department of Urology, James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Cell Biochem 107:179-88. 2009
    ..Thus, the pharmacological modulation of RBM3 and CIRBP may represent novel therapeutic approaches for prostate cancer...
  30. ncbi request reprint Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology
    Julie M Myers-Irvin
    Department of Urology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Cancer Res 65:7145-50. 2005
    ..This information has provided a potential model of BLCA-4 action. Overexpression of BLCA-4 seems to increase the growth rate in cells and also causes cells to express a more tumorigenic phenotype...
  31. ncbi request reprint Fingerprinting the diseased prostate: associations between BPH and prostate cancer
    Uzma S Shah
    Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    J Cell Biochem 91:161-9. 2004
    ..Understanding the fingerprints of these diseases is providing novel markers and treatment strategies for both BPH and prostate cancer...
  32. ncbi request reprint Efficacy of BTA stat, cytology, and survivin in bladder cancer surveillance over 5 years in patients with spinal cord injury
    Benjamin Davies
    Department of Urology, University of Pittsburgh School of Medicine, Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Urology 66:908-11. 2005
    ..The incidence of bladder cancer in patients with SCI is up to 20 times greater than in the general population. However, bladder cancer biomarkers have not been assessed in this population...
  33. ncbi request reprint Highly specific urine-based marker of bladder cancer
    Thu Suong Van Le
    Department of Urology, University of Pittsburgh, Cancer Institute, Pittsburgh, Pennsylvania, USA
    Urology 66:1256-60. 2005
    ..In this study, a sandwich immunoassay was used to measure BLCA-4 in urine samples from patient populations with various urologic conditions and healthy individuals...
  34. ncbi request reprint Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
    Vinata B Lokeshwar
    Department of Urology, University of Miami, Miami, Florida 33101, USA
    Urology 66:35-63. 2005
    ..Therefore, use of bladder tumor markers in the management of patients with bladder cancer will require the willingness of both urologists and clinicians to accept them...
  35. ncbi request reprint Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer
    Manimalha Balasubramani
    Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Res 66:763-9. 2006
    ..These results suggest an involvement of hnRNP F and CKB in colorectal cancer. Additionally, they suggest that hnRNP F is a potential marker for colorectal cancer progression...
  36. ncbi request reprint Use of the novel marker BLCA-1 for the detection of bladder cancer
    Julie M Myers-Irvin
    Department of Urology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    J Urol 174:64-8. 2005
    ..We examined the expression pattern of one of these proteins, BLCA-1, in tissue and urine samples from individuals with bladder cancer as well as in samples from normal controls...
  37. ncbi request reprint Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer
    Eddy S Leman
    Department of Urology, University of Pittsburgh School of Medicine, Pennsylvania 15232, USA
    J Cell Biochem 88:599-608. 2003
    ..Overall, these findings support the evidence that HMGI(Y) can be utilized as a marker and prognostic tool for prostate cancer...
  38. ncbi request reprint The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines
    Masaaki Kasai
    Department of Pharmacology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    Cancer Res 63:4927-35. 2003
    ..e., COOH-terminal LIM domain) and by the dominant-negative activity of its NH(2)-terminal domain. Thus, highly related group 3 LIM domain proteins may use distinct mechanisms to modulate steroid hormone receptor transactivation...
  39. ncbi request reprint Vitamin D and prostate cancer
    Badrinath R Konety
    Departments of Urology, Pathology, and Pharmacology, University of Pittsburgh, 5200 Centre Avenue, G 40, Pittsburgh, PA 15232, USA
    Urol Clin North Am 29:95-106, ix. 2002
    ..There is now considerable evidence suggesting a role for vitamin D in prostate cancer. In this article, we have reviewed the current evidence supporting the use of vitamin D in the prevention and treatment of prostate cancer...
  40. ncbi request reprint Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps
    Gisela Brunagel
    Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    J Cell Biochem 91:365-74. 2004
    ..CC3 and CC4 are expressed earlier in the evolution of adenomatous polyps. Development of an assay to these proteins may serve as a new method for early detection of colorectal cancer...
  41. ncbi request reprint Nuclear matrix protein alterations associated with colon cancer metastasis to the liver
    Gisela Brunagel
    Department of Medicine, Division of Gastroenterology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 8:3039-45. 2002
    ..These were compared with colon cancer NMP patterns, along with several primary cell systems and lines...
  42. doi request reprint (Z)-1,1-Dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane induces concentration-dependent growth inhibition, apoptosis, and coordinates regulation of apoptotic genes in TRAMP cells
    Catherine A Thomas
    Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15260, USA
    Urol Oncol 26:378-85. 2008
    ..2-(4-methoxyphenyl)-A(II) inhibits proliferation and induces apoptosis in the in vivo-adaptable TRAMP cells, suggesting the compound should be further examined in preclinical models...
  43. ncbi request reprint Androgens and prostate cancer: are the descriptors valid?
    Pradip Roy-Burman
    Cancer Biol Ther 4:4-5. 2005
    ..It is thus suggested that "androgen-independent (AI)" cancer should be more accurately termed "androgen depletion-independent (ADI)" cancer...
  44. ncbi request reprint The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer
    Gisela Walgenbach-Brunagel
    Department of Surgery, University of Bonn, Bonn, Germany
    J Cell Biochem 104:286-94. 2008
    ..This initial study showed the potential of CCSA-2 to serve as a highly specific blood based marker for colon cancer. Although potentially promising, the results of this study must be confirmed in larger independent validation studies...
  45. ncbi request reprint Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy
    Evan T Keller
    Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
    Cancer Res 67:9613-5. 2007
  46. ncbi request reprint Noninvasive testing for colorectal cancer: a review
    Daniel L Ouyang
    Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Am J Gastroenterol 100:1393-403. 2005
    ....
  47. ncbi request reprint Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia
    Shinji Sakamoto
    Pharmaceutical Frontier Research Laboratories, JT, Inc, Yokohama City, Japan
    J Biomol Screen 8:701-11. 2003
    ..These detection methods not only may be useful for diagnostic purposes but may also be used to identify suppressors of CYR61 expression for BPH therapy employing high-throughput screening assays...

Research Grants16

  1. MTOPS Biomarker Unit at the University of Pittsburgh
    Robert Getzenberg; Fiscal Year: 2004
    ..As a component of the MTOPS Consortium, these studies should provide the development of novel biomarkers with utility in diagnosing and characterizing BPH. ..
  2. Specific Biomarkers in Bladder Cancer Prevention
    Robert Getzenberg; Fiscal Year: 2005
    ....
  3. VITAMIN D EFFECTS ON HUMAHN PROSTATE GROWTH
    Robert Getzenberg; Fiscal Year: 2001
    ..These studies are likely to reveal important information about the role of vitamin D and its interplay with androgens in the normal prostate and in BPH. ..
  4. Conference--Prouts Neck Prostate Cancer
    Robert Getzenberg; Fiscal Year: 2006
    ..abstract_text> ..